Last reviewed · How we verify
hCG-IBSA
At a glance
| Generic name | hCG-IBSA |
|---|---|
| Sponsor | IBSA Institut Biochimique SA |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics of FSH and hCG Following Multiple Dose of Gonadotropins-IBSA. (PHASE1)
- Pharmacokinetics of FSH and hCG After a Single Subcutaneous Injection of Gonadotropins-IBSA (PHASE1)
- Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol
- COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLES (PHASE3)
- Patient's Preferences About Subcutaneous or Vaginal Progesterone Administration for Luteal Phase Support (NA)
- Different Induction Protocols in PCOS After Clomiphene Citrate Failed Pregnancy in Non-IVF Cycles (PHASE4)
- Effect of Ubiquinol Supplementation on Ovulation Induction in Clomiphene Citrate Resistance (PHASE2, PHASE3)
- Comparative Bioavailability Study of Human Chorionic Gonadotropin (hCG)-IBSA Versus a Marketed hCG Formulation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hCG-IBSA CI brief — competitive landscape report
- hCG-IBSA updates RSS · CI watch RSS
- IBSA Institut Biochimique SA portfolio CI